Phase Ii Trial of Mitozolomide in Patients with Advanced Ovarian Cancer: A Study of the Eortc Gynecological Cancer Cooperative Group

J. P. Neijt Department of Medicine, Utrecht University Hospital, Utrecht; Rotterdam Cancer Institute, Rotterdam; Free University, Amsterdam; Netherlands, Centre Leon Berard, Lyon; Institute Gustave-Roussy, Villejuif, France; institut Jules Bordet, and Eortc Data Center, Brussels, Belgium; Ospedale Ginecologico Santa Anna, Torino, Italy

M. E. L. van der Burg Department of Medicine, Utrecht University Hospital, Utrecht; Rotterdam Cancer Institute, Rotterdam; Free University, Amsterdam; Netherlands, Centre Leon Berard, Lyon; Institute Gustave-Roussy, Villejuif, France; institut Jules Bordet, and Eortc Data Center, Brussels, Belgium; Ospedale Ginecologico Santa Anna, Torino, Italy

J. P. Guastalla Department of Medicine, Utrecht University Hospital, Utrecht; Rotterdam Cancer Institute, Rotterdam; Free University, Amsterdam; Netherlands, Centre Leon Berard, Lyon; Institute Gustave-Roussy, Villejuif, France; institut Jules Bordet, and Eortc Data Center, Brussels, Belgium; Ospedale Ginecologico Santa Anna, Torino, Italy

M. George Department of Medicine, Utrecht University Hospital, Utrecht; Rotterdam Cancer Institute, Rotterdam; Free University, Amsterdam; Netherlands, Centre Leon Berard, Lyon; Institute Gustave-Roussy, Villejuif, France; institut Jules Bordet, and Eortc Data Center, Brussels, Belgium; Ospedale Ginecologico Santa Anna, Torino, Italy

M. Piccart Department of Medicine, Utrecht University Hospital, Utrecht; Rotterdam Cancer Institute, Rotterdam; Free University, Amsterdam; Netherlands, Centre Leon Berard, Lyon; Institute Gustave-Roussy, Villejuif, France; institut Jules Bordet, and Eortc Data Center, Brussels, Belgium; Ospedale Ginecologico Santa Anna, Torino, Italy

J. Vermorken Department of Medicine, Utrecht University Hospital, Utrecht; Rotterdam Cancer Institute, Rotterdam; Free University, Amsterdam; Netherlands, Centre Leon Berard, Lyon; Institute Gustave-Roussy, Villejuif, France; institut Jules Bordet, and Eortc Data Center, Brussels, Belgium; Ospedale Ginecologico Santa Anna, Torino, Italy

F. Carnino Department of Medicine, Utrecht University Hospital, Utrecht; Rotterdam Cancer Institute, Rotterdam; Free University, Amsterdam; Netherlands, Centre Leon Berard, Lyon; Institute Gustave-Roussy, Villejuif, France; institut Jules Bordet, and Eortc Data Center, Brussels, Belgium; Ospedale Ginecologico Santa Anna, Torino, Italy

N. Rotmensz Department of Medicine, Utrecht University Hospital, Utrecht; Rotterdam Cancer Institute, Rotterdam; Free University, Amsterdam; Netherlands, Centre Leon Berard, Lyon; Institute Gustave-Roussy, Villejuif, France; institut Jules Bordet, and Eortc Data Center, Brussels, Belgium; Ospedale Ginecologico Santa Anna, Torino, Italy

show all

References

Gibson N. W, Hickman J. A, Erickson LC. DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl)imidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one. Cancer res 1984; 44: 1772–5
PubMed Web of Science ®Google Scholar
Fodstad O., Aamdal S., Pihl A. Activity of mitozolomide (NSC 353451), a new irnidazotetrazine, against xenografts from human melanomas, and lung and colon carcinomas. Cancer Res 1985; 45: 1778–86
PubMedGoogle Scholar
Joss R. A, Ryssel H. J, Bischoff A. K, Goldhirsch A., Brunner KW. Abbreviated phase I clinical trial of i.v. mitozolomide. Cancer Treat Rep 1986; 70: 797–8
PubMedGoogle Scholar
Newlands E. S, Blackledge G., Slack JA. Phase I clinical trial of mitozolomide. Cancer Treat Rep 1985; 69: 801–5
PubMedGoogle Scholar
WHO Handbook for reporting Results of Cancer Treatment. WHO, Geneva 1979
Google Scholar
Harding M., Northcott D., Smyth J., Stuart N. SA, Green J. A, Newlands E. Phase II evaluation of mitozolomide in ovarian cancer. Br J Cancer 1988; 57: 113–4
PubMedGoogle Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Phase Ii Trial of Mitozolomide in Patients with Advanced Ovarian Cancer: A Study of the Eortc Gynecological Cancer Cooperative Group

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Phase Ii Trial of Mitozolomide in Patients with Advanced Ovarian Cancer: A Study of the Eortc Gynecological Cancer Cooperative Group

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date